Dose-related biochemical markers of renal injury after sevoflurane versus desflurane anesthesia in volunteers

Anesthesia and Analgesia

Volumn 85, Issue 5, 1997, Pages 1154-1163

  Eger II, Edmond I ^a   Gong, Diane ^a   Koblin, Donald D ^a   Bowland, Terri ^a   Ionescu, Pompiliu ^a   Laster, Michael J ^a   Weiskopf, Richard B ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ALBUMIN; BILIRUBIN; BIOCHEMICAL MARKER; CARBON DIOXIDE; CREATININE; DESFLURANE; ETHER DERIVATIVE; FLUORIDE; GLUCOSE; GLUTATHIONE TRANSFERASE; SEVOFLURANE; VINYL DERIVATIVE;

ADULT; ANESTHESIA; ARTICLE; CONTROLLED STUDY; CREATININE URINE LEVEL; DOSE RESPONSE; GAS FLOW; GLOMERULUS; GLUCOSURIA; HUMAN; HUMAN EXPERIMENT; INHALATIONAL DRUG ADMINISTRATION; INTRAVENOUS DRUG ADMINISTRATION; KIDNEY INJURY; KIDNEY PROXIMAL TUBULE; LONG TERM EXPOSURE; MALE; MINIMUM LUNG ALVEOLUS CONCENTRATION; NEPHROTOXICITY; NORMAL HUMAN; PRIORITY JOURNAL; PROTEINURIA; UREA NITROGEN BLOOD LEVEL;

ADULT; ANESTHESIA, GENERAL; ANESTHETICS, INHALATION; BIOLOGICAL MARKERS; DOSE-RESPONSE RELATIONSHIP, DRUG; ETHERS; FLUORIDES; HUMANS; HYDROCARBONS, FLUORINATED; ISOFLURANE; KIDNEY DISEASES; KIDNEY GLOMERULUS; LIVER DISEASES; MALE; METHYL ETHERS; TEMPERATURE; TIDAL VOLUME;

EID: 0030816875     PISSN: 00032999     EISSN: None     Source Type: Journal    
DOI: 10.1097/00000539-199711000-00036     Document Type: Article

References (37)

1. Frink EJ Jr, Ghantous H, Malan T, et al. Plasma inorganic fluoride with sevoflurane anesthesia: correlation with indices of hepatic and renal function. Anesth Analg 1992;74:231-5.
2. Wallin RF, Regan BM, Napoli MD, Stern IJ, Sevoflurane: a new inhalational anesthetic agent. Anesth Analg 1975;54:758-65.
3. Morio M, Fujii K, Satoh N, et al. Reaction of sevoflurane and its degradation products with soda lime: toxicity of the byproducts. Anesthesiology 1992;77:1155-64.
4. Mazze RI, Cousins MJ, Kosek JC. Dose-related methoxyflurane nephrotoxicity in rats: a biochemical and pathologic correlation. Anesthesiology 1972;36:571-87.
5. Gonsowski CT, Laster MJ, Eger EI II, et al. Toxicity of compound A in rats: effect of increasing duration of administration. Anesthesiology 1994;80:566-73.
6. Gonsowski CT, Laster MJ, Eger EI II, et al. Toxicity of compound A in rats: effect of a 3-hour administration. Anesthesiology 1994;80:556-65.
7. Keller KA, Callan C, Prokocimer P, et al. Inhalation toxicity study of a haloalkene degradant of sevoflurane, compound A (PIPE), in Sprague-Dawley rats. Anesthesiology 1995;83: 1220-32.
8. Frink EJ Jr, Malan TP Jr, Isner RJ, et al. Renal concentrating function with prolonged sevoflurane or enflurane anesthesia in volunteers. Anesthesiology 1994;80:1019-25.
9. Tsukamoto N, Hirabayashi Y, Shimizu R, Mitsuhata H. The effects of sevoflurane and isoflurane anesthesia on renal tubular function in patients with moderately impaired renal function. Anesth Analg 1996;82:909-13.
10. Higuchi H, Sumikura H, Sumita S, et al. Renal function in patients with high serum fluoride concentrations after prolonged sevoflurane anesthesia. Anesthesiology 1995;83:449-58.
11. Mazze RI, Jamison R. Renal effects of sevoflurane [editorial]. Anesthesiology 1995;83:443-5.
12. Eger EI II, Koblin DD, Bowland T, et al. Nephrotoxicity of sevoflurane vs. desflurane anesthesia in volunteers. Anesth Analg 1997;84:160-8.
13. Kandel L, Laster MJ, Eger EI II, et al. Nephrotoxicity in rats undergoing a 1-hour exposure to Compound A. Anesth Analg 1995;81:559-63.
14. Yasuda N, Lockhart SH, Eger EI II, et al. Kinetics of desflurane, isoflurane, and halothane in humans. Anesthesiology 1991;74: 489-98.
15. Yasuda N, Lockhart SH, Eger EI II, et al. Comparison of kinetics of sevoflurane and isoflurane in humans. Anesth Analg 1991; 72:316-24.
16. Eger EI II. Stability of I-653 in soda lime. Anesth Analg 1987;66: 983-5.
17. Sutton TS, Koblin DD, Gruenke LD, et al. Fluoride metabolites following prolonged exposure of volunteers and patients to desflurane. Anesth Analg 1991;73:180-5.
18. Sundberg A, Appelkvist E-L, Dallner G, Nillson R. Glutathione transferases in the urine: sensitive methods for detection of kidney damage induced by nephrotoxic agents in humans. Environ Health Perspect 1994;102(Suppl):293-6.
19. Scheller MS, Partridge BL, Saidman LJ. MAC of sevoflurane in humans and the New Zealand white rabbit. Can Anaesth Soc J 1988;35:153-6.
20. Rampil IJ, Lockhart S, Zwass M, et al. Clinical characteristics of desflurane in surgical patients: minimum alveolar concentration. Anesthesiology 1991;74:429-33.
21. Shihabi ZK, Konen JC, O'Conner ML. Albuminuria vs urinary total protein for detecting chronic renal disorders. Clin Chem 1991;37:621-4.
22. Jin L, Baillie TA, Davis MR, Kharasch ED. Nephrotoxicity of sevoflurane compound A [fluoromethyl-2,2-difluoro-1-(trifluoromethyl)vinyl ether] in rats: evidence for glutathione and cysteine conjugate formation and the role of renal cysteine conjuguate β-lyase. Biochem Biophy Res Commun 1995;210: 498-506.
23. Kharasch ED, Thorning D, Garton K, et al. Role of renal cysteine conjugate β-lyase in the mechanism of compound A nephrotoxicity in rats. Anesthesiology 1997;86:160-71.
24. Martin JL, Laster MJ, Kandel L, et al. Metabolism of compound A by renal cysteine-S-conjugate β-lyase is not the mechanism of compound A-induced renal injury in the rat. Anesth Analg 1996;82:770-4.
25. Odum J, Green T. The metabolism and nephrotoxicity of tetrachloroethylene in the rat. Toxicol Appl Pharmacol 1984;76: 306-18.
26. Hinchman CA, Ballatori N. Glutathione conjugation and conversion to mercapturic acids can occur as an intrahepatic process. J Toxicol Environ Health 1994;41:387-409.
27. Dekant W, Vamvaks S, Anders MW. Bioactivation of nephrotoxic haloalkenes by glutathione conjugation: formation of toxic and mutagenic intermediatss by cysteine conjugate β-lyase. Drug Metab Rev 1989;20:43-83.
28. Lash LH, Nelson RM, Van Dyke RA, Anders MW. Purification and characterization of human kidney cytosolic conjugate β-lyase activity. Drug Metab Disp 1990;18:50-4.
29. Eger EI II, Ionescu P, Koblin DD, Weiskopf RB. Compound A: solubility in saline and olive oil - destruction by blood. Anesth Analg 1996;83:849-53.
30. Rieselbach RE, Garnick MB. Nephropathies caused by antineoplastic agents. In: Massry SG, Glassock RJ, eds. Textbook of nephrology. 3rd Ed. Baltimore: Williams & Wilkins, 1995:936-8.
31. Bennett WM. Drug-induced nephrotoxicity: mechanisms. In: Drugs and renal disease. 2nd ed. Monographs in Clincial Pharmacology. New York: Churchill Livingstone, 1986:76-83.
32. Eger EI II, Laster MJ, Winegar R, et al. Compound A induces sister chromatid exchanges in chinese hamster ovary cells. Anesthesiology 1997;86:918-22.
33. Kasiske BL, Keane WF. Laboratory assessment of renal disease: clearance, urinalysis, and renal biopsy. In: Brenner BM, ed. Brenner & Rector's the kidney. 5th ed. Philadelphia: WB Saunders, 1996:1137-74.
34. Fang ZX, Kandel L, Laster MJ, et al. Factors affecting production of compound A from the interaction of sevoflurane with Baralyme® and soda lime. Anesth Analg 1996;82:775-81.
35. Moriwaki G, Bito H, Ikeda K. Consumed soda lime inhibits degradation of sevoflurane in an anesthetic circuit [abstract]. Anesthesiology 1996;85:A356.
36. Frink EJ Jr, Green WB Jr, Brown EA, et al. Compound A concentrations during sevoflurane anesthesia in children. Anesthesiology 1996;84:566-71.
37. Laster MJ, Gong D, Kerschmann RL, et al. Acetaminophen predisposes to renal and hepatic injury from compound A in the fasting rat. Anesth Analg 1997;84:169-72.